BCM
ELDN icon

Bridgeway Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Bridgeway Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,400
Closed -$86.5K – 1239
2025
Q3 		$86.5K Hold
33,400
– – ﹤0.01% 1124
2025
Q2 		$90.5K Hold
33,400
– – ﹤0.01% 1087
2025
Q1 		$113K Hold
33,400
– – ﹤0.01% 1017
2024
Q4 		$138K Hold
33,400
– – ﹤0.01% 1065
2024
Q3 		$83.2K Hold
33,400
– – ﹤0.01% 1175
2024
Q2 		$88.2K Buy
+33,400
New +$79.7K ﹤0.01% 1169
2017
Q1 		– Sell
-617
Closed -$98K – 1408
2016
Q4 		$98K Sell
617
-2,178
-78% -$417K ﹤0.01% 1358
2016
Q3 		$693K Buy
2,795
+2,178
+353% +$797K 0.01% 946
2016
Q2 		$551K Buy
617
+247
+67% +$272K 0.01% 1003
2016
Q1 		$337K Buy
370
+308
+497% +$302K 0.01% 1183
2015
Q4 		$87K Hold
62
– – ﹤0.01% 1382
2015
Q3 		$104K Hold
62
– – ﹤0.01% 1391
2015
Q2 		$133K Buy
+62
New +$120K ﹤0.01% 1408

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Bridgeway Capital Management's ELDN Position: Q4 2025 in Review

Bridgeway Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q4 2025, closing a stake of 33,400 shares — an estimated $86.5K sold.

Bridgeway Capital Management first reported a position in ELDN in Q2 2015 and held it in 13 quarters. The position peaked at $693K in Q3 2016. 95 funds tracked by Wall St. Rank hold ELDN as of Q4 2025.

  • Bridgeway Capital Management reported no remaining Eledon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 33,400 Eledon Pharmaceuticals shares in Q4 2025, an estimated $86.5K.
  • Bridgeway Capital Management first reported a position in Eledon Pharmaceuticals in Q2 2015 and held it in 13 quarters.
  • Bridgeway Capital Management's Eledon Pharmaceuticals position peaked at $693K in Q3 2016.
  • 95 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2025.

Based on Bridgeway Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.